Best Growth Stocks to Buy for June 22nd

The article highlights three Zacks #1 Rank stocks—H&R Block, DaVita, and Pitney Bowes—supported by improving earnings estimates over the last 60 days, with consensus EPS rising 4.0%, 6.4%, and nearly 11%, respectively. All three names also screen cheaply on PEG, ranging from 0.53 to 0.79, versus industry PEGs of 0.84 to 2.17. The piece is primarily a stock-selection screen rather than a company-specific catalyst, so near-term market impact should be limited.

Analysis

This reads less like a growth-screen victory lap and more like a signal that the market is paying up for earnings revisions in unloved, cash-generative businesses. The common factor is not top-line acceleration; it is estimate inflection against low multiples, which tends to work best when macro volatility is fading and investors are forced to chase earnings quality over narrative. That setup can persist for weeks to a few months, but it is fragile if rates reprice higher or if the market rotates back into duration and mega-cap growth.

The second-order effect is that these names may be competing for the same incremental capital: systematic growth screens, small-cap value funds, and “quality at a discount” allocators. That makes the move self-reinforcing, but also crowded at the factor level rather than the stock level. PBI looks like the most reflexive beneficiary because its re-rating case depends on the market believing the operating story is no longer structurally broken; if execution slips even modestly, the multiple compression can reverse faster than fundamentals.

The article’s quantum-computing teaser is more important as a sentiment read than a direct trade signal: it suggests broad speculation is being paired with defensive-growth names, which often happens late in a factor cycle. That creates an interesting contrast with the listed stocks: these are not “story” names, they are estimate-up revisions with low PEGs, meaning the upside is likely to be slower but more durable. The contrarian risk is that the market is over-assigning permanence to the revision trend; one disappointing print or guide-down can erase several weeks of outperformance in these lower-liquidity setups.

Key Decisions for Investors

• Go long HRB for 4-8 weeks as a mean-reversion/earnings-revision trade; target a 10-15% upside if the market continues rewarding low-PEG estimate revisions, with tight risk defined by a 5-7% stop if momentum rolls over.
• Buy DVA on pullbacks and treat it as the cleanest quality compounder in the group; the risk/reward is best over 3-6 months because the estimate revisions are less likely to be reversed quickly, but use a smaller size given lower catalyst frequency.
• Trade PBI tactically rather than structurally: long only into strength, or consider selling upside calls against a long equity position. The thesis is a fast re-rating, but the downside is equally fast if investors start questioning the durability of the improvement.
• Pair trade: long HRB/DVA basket vs short a high-multiple growth ETF or name set over the next 1-2 months. The expression is a factor trade on revisions-to-valuation spread, with better odds if rates stay range-bound.
• Avoid chasing after a one-day pop; enter on intraday weakness or after the first post-article consolidation. These names likely work as confirmation trades, not breakout trades, and are vulnerable to reversal if the market broadens out into mega-cap tech.